TLSI TriSalus Life Sciences, Inc.

4.440USD+1.37%Mkt Cap: 269.70M $P/E: —

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat live…

Key Statistics

Company
Market Cap269.70M USD
Enterprise Value254.14M USD
Revenue (TTM)45.08M USD
Gross Profit38.19M USD
Net Income (TTM)-39.23M USD
Revenue/Share0.90 USD
Last Price4.440 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees102
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.28
PEG—
EV/EBITDA-8.49
EV/Revenue5.64
P/S5.90
P/B40.37
EPS (TTM)-1.22
EPS (Forward)-0.25
52W Range
2.20039% of range7.950
52W High7.950 USD
52W Low2.200 USD
Profitability
Gross Margin84.57%
Oper. Margin-86.03%
EBITDA Margin-66.44%
Profit Margin-86.88%
ROE115.85%
ROA-111.03%
Growth
Revenue Growth1.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.01M USD
CapEx (TTM)918.00K USD
FCF Margin-24.13%
FCF Yield-4.03%
Net Debt-11.86M USD
Net Debt/EBITDA0.40
Balance Sheet
Debt/Equity-1.02
Current Ratio5.35
Quick Ratio4.72
Book Value/Sh0.11 USD
Cash/Share0.75 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.40 USD
Upside (mean)+134.2%
Target Range7.000 USD – 14.00 USD
7.000+134.2% to mean14.00
# Analysts5
Ownership
Shares Out.61.57M
Float49.82M
Insiders33.96%
Institutions35.73%
Short Interest
Short Ratio30.3d
Short % Float7.17%
Short % Out.5.43%
Shares Short3.35M
Short (prev mo.)3.79M
Technical
SMA 504.884 (-9.1%)
SMA 2004.675 (-5.0%)
Beta0.44
S&P 52W Chg14.58%
Avg Vol (30d)284.64K
Avg Vol (10d)801.32K
Technical Indicators
RSI (14)42.7
MACD-0.1627
MACD Signal-0.1053
MACD Hist.-0.0573
BB Upper5.280 USD
BB Middle4.665 USD
BB Lower4.050 USD
BB Width26.36%
ATR (14)0.3556 USD
Vol Ratio (20d)0.37x